Relay Therapeutics, Inc.

Relay Therapeutics, Inc. is a U.S.-based clinical-stage precision medicine company focused on discovering and developing small-molecule therapies for cancer and genetic diseases. The company’s work centers on its Dynamo platform, which combines computational and experimental methods to design drugs against protein targets that have been difficult to address with traditional approaches.

−1 948,4 %

−1 800,6 %

+53,4 %

22.61

22.61

— Relay Therapeutics, Inc.
%
Clinical-stage product candidates0% Small-molecule therapeutic candidates in clinical development, including the lead oncology program.
Preclinical pipeline0% Discovery-stage programs in precision oncology and genetic diseases before first-in-human testing.
Platform-enabled drug discovery0% Computational and experimental capabilities used to identify and optimize new drug candidates.
Collaboration and license revenue100% Revenue from research collaborations, licenses, and related contractual arrangements.

Relay Therapeutics does not currently sell approved products to end patients; its economic counterparties are primarily...

  • Pharmaceutical collaboration partnersprimary

    Companies that license programs or collaborate on discovery and development to access Relay's platform and assets.

  • Biotechnology partnersprimary

    Smaller drug developers that may co-develop or license programs for specific targets or indications.

  • Healthcare providers and physicianssecondary

    Potential prescribers of approved therapies, especially specialists in oncology and genetic disease.

  • Third-party payorssecondary

    Insurers and reimbursement bodies that would influence access and uptake after approval.

  • Patients with precision medicine indicationssecondary

    Patients identified by molecular diagnostics for targeted treatment in oncology or genetic disease.

Relay Therapeutics is headquartered in Cambridge, Massachusetts and conducts research and development primarily from...

  • •Headquartered in Cambridge, Massachusetts
  • •Core research and development is U.S.-based
  • •Relies on foreign CMOs for certain development materials
  • •Clinical and regulatory activities may extend to foreign jurisdictions
  • •No country-level revenue disclosure available

Relay Therapeutics is focused on advancing a platform-led pipeline in precision oncology and genetic disease, using...

01
Advance clinical-stage programsshort-term

Clinical proof-of-concept is the key value driver for a biotech with no marketed products.

02
Broaden the pipelinemedium-term

Multiple shots on goal reduce dependence on any single asset or indication.

03
Leverage the Dynamo platformmedium-term

Platform productivity supports repeatable discovery and differentiation versus single-asset peers.

04
Use partnerships selectivelyshort-term

Collaborations can provide validation, resources, and development support.

Relay Therapeutics faces the typical risks of a clinical-stage biotech: trial failure, regulatory delays, and...

high

Failure in pivotal clinical development

The company has not yet successfully completed large-scale pivotal trials, so late-stage attrition remains a major risk.

Scope
Lead and pipeline candidates
Materiality
high
high

Regulatory approval risk

Even promising data may not translate into approval if regulators require additional evidence or identify safety issues.

Scope
All product candidates
Materiality
high
high

Third-party manufacturing and supply chain dependence

The company relies on foreign CMOs and external suppliers for investigational materials and APIs.

Scope
Clinical and preclinical supply
Materiality
high
medium

Collaboration and licensing execution risk

Milestones, reimbursements, and development support depend on counterparties and contract terms.

Scope
Genentech Agreement, Elevar Agreement
Materiality
medium
medium

Future commercialization and reimbursement risk

If approved, uptake will depend on physician adoption and third-party payor coverage.

Scope
Potential marketed products
Materiality
medium
ASC 606 collaboration revenue
Genentech and Elevar-related revenue
Clinical trial accruals
R&D expense volatility
Prepaid expenses and accrued R&D
Quarterly operating expense timing
Lease accounting
G&A and facility cost presentation
Fair value estimates
Non-cash gains/losses and balance sheet estimates

Neuraxis, INC

NRXS · Electromedical & Electrotherapeutic Apparatus

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

Rein Therapeutics, Inc.

RNTX · Pharmaceutical Preparations

TG THERAPEUTICS, INC.

TGTX · Pharmaceutical Preparations

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

CELZ · Biological Products, (No Diagnostic Substances)

Century Therapeutics, Inc.

IPSC · Biological Products, (No Diagnostic Substances)

: 29.4.2026